Alkaptonuria: a very rare metabolic disorder

Area of Science:

• Biochemistry and Genetics
• Rare Metabolic Disorders
• Human Physiology

Background:

• Alkaptonuria (AKU) is an autosomal recessive disorder stemming from homogentisate 1,2 dioxygenase (HGD) deficiency.
• This deficiency leads to the accumulation of homogentisic acid (HGA), which deposits in connective tissues, causing ochronosis and arthropathy.
• AKU presents with characteristic symptoms including urine darkening, blue-dark connective tissue pigmentation, and severe joint degeneration.

Purpose of the Study:

• To review classical and recent findings on Alkaptonuria (AKU).
• To highlight the genetic basis, clinical manifestations, and disease progression of AKU.
• To discuss current treatment options, such as nitisinone, for managing HGA production.

Main Methods:

• Literature review of classical and recent studies on Alkaptonuria (AKU).
• Analysis of genetic defects within the HGD gene.
• Compilation of clinical data on disease progression and complications.

Main Results:

• AKU is characterized by HGD deficiency, leading to HGA accumulation and deposition in tissues.
• The disease progresses through distinct stages: darkened urine, ochronosis, and ochronotic arthropathy.
• Specific ethnic groups, notably in Slovakia and the Dominican Republic, exhibit a higher incidence of AKU.

Conclusions:

• Alkaptonuria (AKU) is a rare, progressive metabolic disorder with significant clinical impact.
• Understanding the HGD gene defect and HGA metabolism is crucial for AKU management.
• Nitisinone offers a therapeutic approach by reducing HGA production, representing a significant advancement in AKU treatment.